We could not find any results for:
Make sure your spelling is correct or try broadening your search.
VanEck announced today its distributions per share for its VanEck Vectors® exchange-traded funds. The following dates apply to distribution declarations for the funds listed below:...
VanEck announced today its regular distribution per share for the following VanEck Vectors® equity exchange-traded fund. ...
ESPO provides targeted exposure to “the future of sports”: video game and related software developers, streaming services, companies involved in eSports events, and more VanEck today...
VanEck announced today its regular distributions per share for the VanEck Vectors® equity exchange-traded funds. Ex-Date...
VanEck announced today its regular distributions per share for its VanEck Vectors® equity exchange-traded funds. Ex-Date Record Date ...
VanEck announced today its regular distributions per share for its VanEck Vectors® equity exchange-traded funds. Ex-Date Record Date ...
- Treatment in Combination with Radiation Doubled Survival Time and Produced Long-Term Cures in Lethal Brain Cancer Model - - Confirms PS-Targeting Antibodies Have a Dual Mechanism of Action that...
--Broad New Patent Covers Peregrine's Lead PS-Targeting Antibody Bavituximab and Similar Agents for the Treatment of All Viral Infections-- --New Patent Covers Applications under Active...
TUSTIN, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHMD) today announced that on November 3, 2009, the Company received notice from the NASDAQ Market...
- 28 of 46 (61%) Patients Receiving Bavituximab in Combination with Docetaxel Achieved Objective Tumor Response by End of Planned Treatment Cycles - - Tumor Response Data Compares Favorably with...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions